Alsana expands ARFID support with personalized eating disorder care

Alsana is expanding treatment options for Avoidant/Restrictive Food Intake Disorder, or ARFID, a condition that remains widely misunderstood despite formal recognition in 2013. The eating disorder center is offering residential, day, and intensive outpatient care in California, Alabama, and virtually across 43 states to address gaps in screening and treatment.

Why it matters: - ARFID can leave people eating too little or too little variety, which can affect nutrition, health, and daily life. - Many adults with ARFID go undiagnosed because providers do not always screen for the disorder. - Early treatment can make a major difference for people dealing with food avoidance, sensory reactions, or fear-based eating patterns.

What happened: - Alsana expanded support for ARFID treatment through personalized eating disorder care. - The treatment center operates in California and Alabama and serves 43 states virtually. - ARFID was formally recognized as an eating disorder diagnosis in 2013.

The details: - The National Eating Disorders Association describes ARFID as a condition where people eat less food or a narrower range of foods. - Drivers of ARFID can include low appetite, strong reactions to tastes, smells, or textures, and fear of choking, vomiting, or getting sick from food. - ARFID is often mistaken for a childhood-only issue, but adults can develop it later in life. - Alsana offers residential treatment, day programs (PHP), and intensive outpatient programs (IOP) for ARFID care.

Between the lines: - The expanded focus points to a broader gap in eating disorder care, especially for adults whose symptoms may not fit common assumptions about picky eating. - Virtual treatment access across 43 states may help reach people who have gone years without evaluation or support. - The release frames early intervention as especially important, reflecting the risk that delayed diagnosis can prolong distress and health problems.

What's next: - More adults may seek screening if awareness of ARFID continues to grow. - Alsana is positioned to direct patients into higher or lower levels of care depending on symptom severity and treatment needs. - Broader recognition of ARFID could push more medical providers to screen for the disorder in both children and adults.